Matches 1 - 50 out of 65 1 2 >


Match Document Document Title
US20110171211 HEAT SHOCK PROTEIN GP96 VACCINATION AND METHODS OF USING SAME  
The invention provides a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a heat shock protein (hsp) gp96 polypeptide. The invention also provides a method of...
US20140170157 METHOD OF SELECTING THERAPEUTIC INDICATIONS  
Methods of treatment for Crohn's disease and multiple sclerosis are disclosed. Also disclosed are methods for repositioning a pharmaceutical by selecting at least one target gene, gene product, or...
US20090155273 REMEDIES FOR INFLAMMATORY BOWEL DISEASES  
Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and...
US20140348853 METHODS OF TREATING RICKETTSIA USING EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) INHIBITORS  
Embodiments of the invention are directed to compounds that inhibit an activity of EPAC proteins and methods of using the same.
US20120294851 Cancer Therapies and Pharmaceutical Compositions Used Therein  
The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides co-therapies comprising oligonucleotides plus other therapies to treat cancer.
US20130302317 Siglec-9 Binding Agents  
The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation...
US20120276192 COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1  
RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory...
US20110002938 HEMATOPOIETIC CELLS EXPRESSING THE PROTEIN KRTCAP3 AND LIGANDS FOR THE PROTEIN KRTCAP3  
The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein KRTCAP3 on the surface of said cells, to methods for isolating said cells and to ligands...
US20130243785 SELECTIVE REMOVAL OF AGE-MODIFIED CELLS FOR TREATMENT OF ATHEROSCLEROSIS  
A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells,...
US20130287790 USE OF JAM-A IN DIAGNOSING AND TREATING LEUKEMIA  
Methods, compositions, and kits are provided for the use of JAM-A in diagnosing and treating leukemia. These methods, compositions, and kits find many uses, for example in diagnosing an individual...
US20070269443 Therapeutic Regimens for Baff Antagonists  
Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course...
US20130336966 CORONIN 1 MODULATORS FOR THE TREATMENT OF AUTOIMMUNE AND LYMPHOPROLIFERATIVE DISORDERS AND MYCOBACTERIAL INFECTIONS  
The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1...
US20120251537 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS  
PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced...
US20130022540 METHODS TO FACILITATE TRANSMISSION OF LARGE MOLECULES ACROSS THE BLOOD-BRAIN, BLOOD-EYE, AND BLOOD-NERVE BARRIERS  
A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispina! space of said human without direct intrathecal injection and positioning said...
US20110097337 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells  
The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking...
US20130224215 A B Cell Depleting Agent for the Treatment of Atherosclerosis  
The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
US20120100152 ANTI-HUMAN CD52 IMMUNOGLOBULINS  
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates...
US20080317749 Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment  
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19,...
US20120039871 METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY  
Methods and materials are provided for selecting and/or treating a subject based on a FcγRIIA polymorphism, or a FcγRIIB polymorphism, or both an FcγRIIA polymorphism and a FcγRIIB polymorphism,...
US20110038860 METHODS FOR INHIBITION OF POLYCLONAL B CELL ACTIVATION AND IMMUNOGLOBULIN CLASS SWITCHING TO PATHOGENIC AUTOANTIBODIES BY BLOCKING CD1-MEDIATED INTERACTIONS  
Pathogenic polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies is inhibited by binding molecules that specifically interfere with CD1 antigen, but do not...
US20140314748 ANTIBODY FORMULATIONS  
The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to...
US20120100069 B-Lymphocyte Targeting Agents for Use in a Method for the Treatment of a Disease  
The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition...
US20130195940 METHOD TO INHIBIT RECRUITMENT OF MONOCYTES AND MACROPHAGES BY AN ICAM-3 INHIBITOR  
The present disclosure relates generally to methods and materials for modulating the recruitment of macrophages or monocytes to sites at which they may contribute to disease initiation or...
US20130309244 METHODS AND COMPOSITIONS COMBINING IMMUNOTHERAPY WITH MONOCYTE ACTIVATION  
Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of...
US20140294807 COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES  
The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly...
US20130195846 COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES  
The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly...
US20140065160 COMBINATION THERAPY  
The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various...
US20120045446 THERAPEUTIC AGENT FOR DISEASES IN WHICH NEOPLASTIC PROLIFERATION OF PLASMA CELLS OCCURS  
The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal...
US20120121594 ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ARTHRITIS  
The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat...
US20120003213 Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity  
The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided...
US20130142811 Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof  
The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and...
US20130171137 METHODS OF TREATING AUTOIMMUNE DISEASES WITH ANTI-FCERI ANTIBODIES  
Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use...
US20090047290 Monoclonal antibodies against beta3 integrins  
Monoclonal antibodies prepared against platelet β3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using...
US20120045447 T CELL COSTIMULATING POLYPEPTIDES AND USES THEREOF  
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the...
US20100310555 COMPOSITIONS WITH HEMATOPOIETIC AND IMMUNE ACTIVITY  
The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and...
US20110117105 METHOD OF TREATING IMMUNE DISEASE USING B-CELL ANTIBODIES  
Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian...
US20080317809 Use of K -252a and Kinase Inhibitors for the Prevention or Treatment of Hmgb1-Associated Pathologies  
The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the...
US20120128685 USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS  
The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in...
US20140147382 IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS  
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially...
US20110059099 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA  
The present invention pertains to the treatment of idiopathic thrombocytopenic purpura (ITP) employing pharmaceutical compositions containing a VLA-4 antagonist as active ingredient. The VLA-4...
US20110300153 ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF  
Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies...
US20120141470 T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF  
The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary...
US20110274657 OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS  
The present disclosure relates to oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptor.
US20130004491 Antibodies Against Phosphorylcholine In Combination Therapy with Biologic Agents  
Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as...
US20140004037 STABILIZATION OF THE ANTI-CD20 ANTIBODY RITUXIMAB  
The invention provides isolated stabilized anti-CD20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and...
US20120237441 ENHANCED B CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY  
Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment...
US20100322849 ENHANCED B CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY  
Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment...
US20090117128 Anti-HPA  
The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet...
US20120027769 ANTI-RHD MONOCLONAL ANTIBODIES  
Anti-RhD monoclonal antibodies and methods for the production thereof.
US20100196394 ANTI-CANCER VACCINE COMPOSITION  
Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor...

Matches 1 - 50 out of 65 1 2 >